- Home
- BWIN vs TRVI Comparison
BWIN vs TRVI Comparison
Compare BWIN & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BWIN
- TRVI
- Stock Information
- Founded
- BWIN 2011
- TRVI 2011
- Country
- BWIN United States
- TRVI United States
- Employees
- BWIN N/A
- TRVI N/A
- Industry
- BWIN Specialty Insurers
- TRVI Biotechnology: Pharmaceutical Preparations
- Sector
- BWIN Finance
- TRVI Health Care
- Exchange
- BWIN Nasdaq
- TRVI Nasdaq
- Market Cap
- BWIN 1.7B
- TRVI 1.4B
- IPO Year
- BWIN 2019
- TRVI 2019
- Fundamental
- Price
- BWIN $26.75
- TRVI $11.10
- Analyst Decision
- BWIN Hold
- TRVI Strong Buy
- Analyst Count
- BWIN 7
- TRVI 9
- Target Price
- BWIN $38.29
- TRVI $20.72
- AVG Volume (30 Days)
- BWIN 1.0M
- TRVI 1.6M
- Earning Date
- BWIN 11-04-2025
- TRVI 11-13-2025
- Dividend Yield
- BWIN N/A
- TRVI N/A
- EPS Growth
- BWIN N/A
- TRVI N/A
- EPS
- BWIN N/A
- TRVI N/A
- Revenue
- BWIN $1,487,497,000.00
- TRVI N/A
- Revenue This Year
- BWIN $10.87
- TRVI N/A
- Revenue Next Year
- BWIN $12.60
- TRVI N/A
- P/E Ratio
- BWIN N/A
- TRVI N/A
- Revenue Growth
- BWIN 10.69
- TRVI N/A
- 52 Week Low
- BWIN $21.26
- TRVI $2.36
- 52 Week High
- BWIN $50.46
- TRVI $11.83
- Technical
- Relative Strength Index (RSI)
- BWIN 56.65
- TRVI 60.59
- Support Level
- BWIN $21.26
- TRVI $10.22
- Resistance Level
- BWIN $24.58
- TRVI $11.82
- Average True Range (ATR)
- BWIN 1.10
- TRVI 0.57
- MACD
- BWIN 0.60
- TRVI -0.05
- Stochastic Oscillator
- BWIN 98.39
- TRVI 55.00
About BWIN The Baldwin Insurance Group Inc. Class A Common Stock
The Baldwin Insurance Group Inc is a United States-based insurance distribution firm. Its products include Business Insurance, Benefits Consulting, Reinsurance, Specialty MGA, Embedded Insurance., Personal insurance, etc.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.